Status:
COMPLETED
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Myocardial Injury
Vaccine Adverse Reaction
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
Detailed Description
Population-based retrospective studies suggest an association between BNT162b2 (Pfizer-BioNTech) vaccination against coronavirus disease 2019 (COVID-19) and myocarditis. While the overall incidence of...
Eligibility Criteria
Inclusion
- Adult health care workers (≥18 years old)
Exclusion
- Acute coronary syndrome, peri/myocarditis, cardiac catheterization, cardiac surgery, cardiac ablation, or any other invasive cardiac procedure within 14 days prior to study enrollment.
- Chronic renal failure (creatinine clearance ≤30 mL/min), or dilated or hypertrophic cardiomyopathy
Key Trial Info
Start Date :
January 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 28 2022
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT05308680
Start Date
January 6 2022
End Date
March 28 2022
Last Update
May 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare zedek MC
Jerusalem, Israel